Showing 4431-4440 of 7638 results for "".
- Synera Approved for At-Home Use to Prevent Needle Stick Discomforthttps://practicaldermatology.com/news/20140604-synera_approved_for_at-home_use_to_prevent_needle_stick_discomfort/2459219/The FDA approved a labeling change that allows Galen US Incorporated's Synera (lidocaine and tetracaine) topical patch to be used at home. Synera is a technological advance that can help prevent needle stick pain associated with superficial IVs and superficial dermatological p…
- Cetaphil Launches the Gentle Power Campaignhttps://practicaldermatology.com/news/20140602-cetaphil_launches_the_gentle_power_campaign/2459221/The new Gentle Power Campaign for Cetaphil brands (Galderma) showcases the brand's products and demonstrates how women balance the demands of their day-to-day lives, just as Cetaphil products balance the daily demands on their skin. Stuart Raetzman, chief executive officer of Galderma Laboratori…
- Ichthyosis Patient Raising Awareness, Funds with Hikehttps://practicaldermatology.com/news/20140531-ichthyosis_patient_raising_awareness_funds_with_hike/2459223/To raise awareness of ichthysosis and funds for research, Brian Gass of St. Louis is hiking the Pacific Crest Trail – 2,600 miles from Mexico to Canada, crossing the Sierras, over about 110 days. The 21-year-old college student has the rare genetic skin disease, as do three siblings. The experience…
- Valeant Sells Fillers to Nestle, Ups Allergan Offerhttps://practicaldermatology.com/news/20140530-valeant_sells_fillers_to_nestle_ups_allergan_offer/2459225/Valeant took two significant steps this week in its pursuit of Allergan. In a deal valued at $1.4 billion in cash, Valeant sold the rights to various aesthetic injectables to Nestle. Nestle is expected to operate Restylane, Perlane, Emervel, Sculptra, and Dysport through Galderma. While the deal a…
- AAD Issues Statement on Drinkable Sunscreenhttps://practicaldermatology.com/news/20140523-aad_issues_statement_on_drinkable_sunscreen/2459231/Recently, “drinkable sunscreen” has gotten media coverage for claims that it provides sun protection through the ingestion of water that allegedly has been infused with electromagnetic waves. The American Academy of Dermatology (AAD) wants to alert consumers that this drink …
- Allergan Physician Customers Voice Strong Support Following Allergan's Rejection of Unsolicited Proposal to Acquire Companyhttps://practicaldermatology.com/news/20140521-allergan_physician_customers_voice_strong_support_following_allergans_rejection_of_unsolicited_proposal_to_acquire_company/2459232/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today announced that it has received a strong outpouring of support from its physician customers, their nurses and office staff members, as well as from patient advocacy groups and medical associations, following the Company's rejection of Va…
- Registration Open for Upcoming ADAM Webinarshttps://practicaldermatology.com/news/20140521-registration_open_for_upcoming_adam_webinars/2459233/The Association of Dermatology Administrators & Managers (ADAM) is holding two upcoming webinars for office administrators and managers. The first webinar—Create an Effective Collections Process—will be presented by Steve Carter, President of Carter-Young, on June 4 at 3pm E…
- New Data Demonstrate Significant Long-term Improvement in Scarring using Neodyne Biosciences embrace® Advanced Scar Therapyhttps://practicaldermatology.com/news/20140519-new_data_demonstrate_significant_long-term_improvement_in_scarring_using_neodyne_biosciences_embrace_advanced_scar_therapy/2459236/Neodyne Biosciences reported a highly significant improvement in scarring for patients treated with embrace® Advanced Scar Therapy versus control at one-year follow-up in a randomized, controlled trial of the device. embrace Advanced Scar Therapy actively relieves the tension surrounding a healing …
- Clinical Trial Finds New Cream Diminishes Symptoms of Psoriasis, Eczemahttps://practicaldermatology.com/news/20140516-clinical_trial_finds_new_cream_diminishes_symptoms_of_psoriasis_eczema/2459237/Findings from an independent study indicate that the antioxidant-based Psorzema Crème formula from derma e® diminishes symptoms of eczema and psoriasis. In an eight-week study, symptomatic participants used Psorzema® Crème, all of whom showed significant improvement in dryness and flaking at the en…
- Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSEhttps://practicaldermatology.com/news/20140516-provectus_biopharmaceuticals_incs_common_shares_begin_trading_on_nyse/2459239/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdra…